Acute promyelocytic leukemia: What are the treatment options?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 587-596

  Ferrara, Felicetto ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Acute promyelocytic leukemia; ATO; ATRA; Treatment options

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOCYTOSIS; LIVER TOXICITY; MAINTENANCE THERAPY; MONOTHERAPY; MORBIDITY; NEUTROPENIA; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT PLANNING;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; REMISSION INDUCTION; TRETINOIN;

EID: 77249169904     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903505115     Document Type: Review

References (75)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004;5:443-50
2. Estey EH, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907
3. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66:181-93
4. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649-58
5. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9
6. Ferrara F, Pinto A. Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research. Rev Recent Clin Trials 2007;2:33-41
7. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91
8. Jurcic JG, Soignet SL, Maslak AP. Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 2007;9:337-44
9. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2006:156-61
10. Sanz MA. Recent advances in the treatment of APL. Clin Adv Hematol Oncol 2006;4:727-9
11. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650-8
12. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15
13. Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973;41:489-96
14. Avvisati G, Petti MC, Lo-Coco F, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100:3141-6
15. Huang ME, Ye YC, Chen SR, et al. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72
16. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acidtreated acute promyelocytic leukemia patients. Blood 1991;78:1413-9
17. Fenaux P, Castaigne S, Dombret H, et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80:2176-81
18. Leong KW, Bosco JJ, Teh A. Advantage of induction therapy with all trans retinoic acid in acute promyelocytic leukaemia in a country with limited transfusion resources: a Malaysian experience. Eur J Haematol 1994;53:237-41
19. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:1390-8
20. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93
21. Latagliata R, Avvisati G, Lo Coco F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged < 60 years. Ann Oncol 1997;8:1273-5
22. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-9
23. Tallman MS, Andersen JW, Schiffer CA, et al. All trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1201-8
24. Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 2006;7:397-405
25. Litzow MR. Arsenic trioxide. Expert Opin Pharmacother 2008;9:1773-85
26. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 2005;12:1-6
27. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992;12:170-1
28. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60
29. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24
30. Carmosino I, Latagliata R, Avvisati G, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004;89:615-7
31. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005;82:224-9
32. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60
33. Stein E, McMahon B, Kwaan H, et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009;22:153-63
34. Schlenk RF, Fröhling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004;18:1798-803
35. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53
36. Adès L, Fenaux P. Is cytarabine required in the treatment of acute promyelocytic leukemia? Updated experience and review of the literature. Clin Adv Hematol Oncol 2006;4:678-82
37. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 1999;13:195-200
38. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107:2627-32
39. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17:131-4
40. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504-10
41. Hu J, Liu F-Y, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106:3342-7
42. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 2006;47:2282-8
43. Disperati P, Minden MD, Gupta V, et al. Acute promyelocytic leukemia in patients aged 70 years and over - a single center experience of unselected patients. Leuk Lymphoma 2007;48:1654-8
44. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or = 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003;17:1085-90
45. Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005;19:230-3
46. Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracyclines monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004;104:3490-3
47. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008;35:418-29
48. Pollicardo N, O'Brien S, Estey EH, et al. Secondary acute promyelocytic leukemia: characteristics and prognosis of 14 patients from a single institution. Leukemia 1996;10:27-31
49. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-37
50. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505-8
51. Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43
52. Sanz MA, Lo Coco F. Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica 2005;90:840-5
53. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 2008;35:401-9
54. Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-84
55. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation:results of the AIDA-2000 trial of the Italian GIMEMA group [abstract]. Blood 2004;104:392a
56. Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. ASCO Meeting Abstracts Part I [abstract]. J Clin Oncol 2007;25:2
57. Avvisati G, Petti MC, Lo Coco F, et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act [abstract]. Blood 2003;102:142a
58. Asou N, Kishimoto Y, Kiyoi H, et al. A randomizedstudy with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR-transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007;110:59-66
59. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007;20:57-65
60. Specchia G, Lo CF, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001;19:4023-8
61. Estey EH. Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:521-34
62. Ferrara F, Palmieri S, Annunziata M, et al. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica 2004;89:621-2
63. Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009;15:1479-84
64. Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant 2009;44:353-9
65. Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, et al. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant 2007;13:997-1004
66. Sanz MA, Labopin M, Gorin NC, et al. Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007;39:461-9
67. Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2006;4:57-62, 76-7
68. Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132:398-409
69. Breccia M, Cimino G, Diverio D, et al. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 2007;92:1273-4
70. Maslak PG, Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of APL. Curr Top Microbiol Immunol 2007;313:205-19
71. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009;113:775-83
72. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008;33:331-8
73. Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia - triggering the differentiation syndrome. Blood 2009. [Epub ahead of print]
74. Dore AI, Santana-Lemos BA, Coser VM, et al. The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol 2007;82:1340-3
75. Cunha De Santis G, Tamarozzi MB, Sousa RB, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica 2007;92:1615-22